SILLAR CLINICAL
ActiveFrom the official registers: KBO 8 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
SILLAR CLINICAL has been active since 2018 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €85,117 and a net result of €9,029. Equity fluctuates too strongly from year to year to read a trend from it. Its solvency ranks better than 21% of 2,077 sector peers (NACE 73, financial year 2025). The computed 12-month bankruptcy probability is 1.0% (low).
Overview
Official details
KBO- Status
- Active since 21-03-2018 Normal situation
- Registered office
- 15 active companies are registered at this address 1 started in the 12 months before. Source: KBO register, as of 1 November 2026.
- Activity
- Market research and public opinion polling NACE 73200and 3 others
- Establishment unit
- 2.274.305.055 9831 Sint-Martens-Latem, since 01-04-2018
- Financial year end
- 31 December
- Peppol
- Reachable since 21-10-2026
Board and ownership
- Otte StijnDirector · since 19-12-2020
- DBD ConsultingDirector · since 26-06-2021
Financial position
- Bankruptcy probabilitywithin 12 months
- 1.0%
- Gross margin
- €637,414
- ▲ 11.4%
- Turnover
- ≈ €1.3m
- estimated
- Profit
- €9,029
- ▲ 31.6%
- Equity
- €85,117
- ▲ 11.9%
- Total assets
- €811,427
- ▲ 25.5%
- Staff
- 5.9 FTE
- ▲ 11.3%
Score breakdownraises risk1 of the last 3 accounts lateEquity €85,117 (10.5% of total assets)Size: 5.9 FTE, total assets €811,427lowers riskSector: Advertising, market research and public relations activities (NACE 73)Show the evidence
Checked score
About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 73, micro). It does better than 20% of them on solvency, 22% on liquidity, 26% on profitability and 62% on growth.
The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 12 days after the deadline. In the sector (NACE 73), the median for financial year 2024 was 6 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
Key points
- Positive: 7th largest employer in Sint-Martens-Latem, Professional and technical services sectorin the Checked rankings No. 7 View
Comparable companies
These companies have the same main activity as SILLAR CLINICAL: market research and public opinion polling (NACE 73200). They are comparable in size and age: total assets between €588,000 and €1.4m, founded between 2016 and 2019.
| Company | Total assets | Gross margin |
|---|---|---|
| SILLAR CLINICAL Sint-Martens-Latem | €0.8m | €0.6m |
| BPACT Leuven | €0.8m | €0.5m |
| BUFFL Mechelen | €1.3m | €1.0m |
| STRAREX Antwerpen | €0.6m | €0.6m |
| WATSON CREATIVE Antwerpen | €0.9m | €0.9m |
| TUSK IC Antwerpen | €1.1m | €1.7m |
| Leuven MindGate Leuven | €1.4m | €0.4m |
Documents
Annual accounts at the NBB
- Annual accounts 2025filed on 24-03-2026
- Annual accounts 2024filed on 03-03-2026
- Annual accounts 2023filed on 31-07-2024
- Annual accounts 2022filed on 10-08-2023
Acts in the Belgian Official Gazette
- Resignations & appointmentsact of 18-02-2026
Articles and registers
- Coordinated articles of associationnotaries' database
- Entry in the KBO registerKBO Public Search
Key facts about SILLAR CLINICAL
- What is the company number of SILLAR CLINICAL?
- The company number of SILLAR CLINICAL is 0692.746.878. The VAT number is the same number with BE in front: BE 0692.746.878.
- Where is SILLAR CLINICAL based?
- The registered office is at Xavier De Cocklaan 66, 9831 Sint-Martens-Latem.Company details
- What does SILLAR CLINICAL do?
- According to the KBO register, the main activity is market research and public opinion polling (NACE 73200).
- What is the legal form of SILLAR CLINICAL?
- The legal form of SILLAR CLINICAL is Public limited company (NV).
- When was SILLAR CLINICAL founded?
- SILLAR CLINICAL was founded on 21-03-2018.
- Is SILLAR CLINICAL still active?
- Yes, SILLAR CLINICAL is an active enterprise in the KBO register.
- How many employees does SILLAR CLINICAL have?
- SILLAR CLINICAL had an average of 5.9 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of SILLAR CLINICAL?
- The turnover in financial year 2025 is ≈ €1.3m. This figure is estimated from the gross margin of €637,414 and 38 comparable companies (NACE 73). It probably lies between €860,000 and €1.7m.
- Is SILLAR CLINICAL profitable?
- In financial year 2025, SILLAR CLINICAL made a profit of €9,029.
- Where can I find the annual accounts of SILLAR CLINICAL?
- SILLAR CLINICAL filed 8 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts 2025 (PDF)
- When are the next annual accounts of SILLAR CLINICAL due?
- SILLAR CLINICAL must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.